Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide in Systemic Mastocytosis
NCT00769587Phase 2Completed
- Sponsor
- CHU Amiens-Picardie
- Start
- Jun 2007
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thalidomide in systemic mastocytosis (SM), sponsored by CHU Amiens-Picardie. Primary endpoint: Objective Response Rate at 6 months. Started Jun 2007; status: completed.
02
Drugs
thalidomide
03
Conditions
systemic mastocytosis (SM)
Beyond the preview
Go deeper on NCT00769587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00769587.